220 related articles for article (PubMed ID: 8892457)
1. Autologous bone marrow transplantation in acute myeloid leukemia: the University of Minnesota experience.
Dusenbery KE; Steinbuch M; McGlave PB; Ramsay NK; Blazar BR; Neglia JP; Litz C; Kersey JH; Woods WG
Int J Radiat Oncol Biol Phys; 1996 Sep; 36(2):335-43. PubMed ID: 8892457
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning in autologous bone marrow transplantation for acute myeloid leukemia.
Dusenbery KE; Daniels KA; McClure JS; McGlave PB; Ramsay NK; Blazar BR; Neglia JP; Kersey JH; Woods WG
Int J Radiat Oncol Biol Phys; 1995 Jan; 31(1):119-28. PubMed ID: 7995742
[TBL] [Abstract][Full Text] [Related]
3. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
Ringdén O; Labopin M; Tura S; Arcese W; Iriondo A; Zittoun R; Sierra J; Gorin NC
Br J Haematol; 1996 Jun; 93(3):637-45. PubMed ID: 8652385
[TBL] [Abstract][Full Text] [Related]
4. Autologous bone marrow transplantation for acute myeloid leukemia in remission or first relapse using monoclonal antibody-purged marrow: results of phase II studies with long-term follow-up.
Ball ED; Wilson J; Phelps V; Neudorf S
Bone Marrow Transplant; 2000 Apr; 25(8):823-9. PubMed ID: 10808202
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM).
Devergie A; Blaise D; Attal M; Tigaud JD; Jouet JP; Vernant JP; Bordigoni P; Ifrah N; Dauriac C; Cahn JY
Blood; 1995 Apr; 85(8):2263-8. PubMed ID: 7718899
[TBL] [Abstract][Full Text] [Related]
6. Improved outcome for high-risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody-purged bone marrow.
Selvaggi KJ; Wilson JW; Mills LE; Cornwell GG; Hurd D; Dodge W; Gingrich R; Martin SE; McMillan R; Miller W
Blood; 1994 Mar; 83(6):1698-705. PubMed ID: 8123862
[TBL] [Abstract][Full Text] [Related]
7. Total body irradiation and cyclophosphamide plus antithymocyte globulin regimen is well tolerated and promotes stable engraftment as a preparative regimen before T cell-replete haploidentical transplantation for acute leukemia.
Fu H; Xu L; Liu D; Liu K; Zhang X; Chen H; Chen Y; Han W; Wang Y; Wang J; Wang F; Huang X
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1176-82. PubMed ID: 24747336
[TBL] [Abstract][Full Text] [Related]
8. Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle.
Michel G; Socié G; Gebhard F; Bernaudin F; Thuret I; Vannier JP; Demeocq F; Leverger G; Pico JL; Rubie H; Mechinaud F; Reiffers J; Gratecos N; Troussard X; Jouet JP; Simonin G; Gluckman E; Maraninchi D
J Clin Oncol; 1997 Jun; 15(6):2238-46. PubMed ID: 9196136
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M
J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086
[TBL] [Abstract][Full Text] [Related]
10. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies.
Socié G; Clift RA; Blaise D; Devergie A; Ringden O; Martin PJ; Remberger M; Deeg HJ; Ruutu T; Michallet M; Sullivan KM; Chevret S
Blood; 2001 Dec; 98(13):3569-74. PubMed ID: 11739158
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia.
Uberti JP; Agovi MA; Tarima S; Haagenson M; Gandham S; Anasetti C; Baker KS; Bolwell BJ; Bornhauser M; Chan KW; Copelan E; Davies SM; Finke J; Hale GA; Kollman C; McCarthy PL; Ratanatharathorn V; Ringdén O; Weisdorf DJ; Rizzo JD
Bone Marrow Transplant; 2011 Jan; 46(1):34-43. PubMed ID: 20400989
[TBL] [Abstract][Full Text] [Related]
12. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study.
Blume KG; Kopecky KJ; Henslee-Downey JP; Forman SJ; Stiff PJ; LeMaistre CF; Appelbaum FR
Blood; 1993 Apr; 81(8):2187-93. PubMed ID: 8471778
[TBL] [Abstract][Full Text] [Related]
13. Improved survival after bone marrow transplantation for early leukemia using busulfan-cyclophosphamide and individualized prophylaxis against graft-versus-host disease: a long-term follow-up.
Aschan J; Carlens S; Hägglund H; Klaesson S; Mattsson J; Remberger M
Clin Transplant; 1999 Dec; 13(6):512-9. PubMed ID: 10617242
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic bone marrow transplantation for chronic myeloid leukemia: a retrospective study of busulfan-cytoxan versus total body irradiation-cytoxan as preparative regimen in Koreans.
Kim I; Park S; Kim BK; Chang HM; Bang SM; Byun JH; Kim DJ; Min WS; Kim HJ; Kim CC
Clin Transplant; 2001 Jun; 15(3):167-72. PubMed ID: 11389706
[TBL] [Abstract][Full Text] [Related]
15. Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation.
Demirer T; Gooley T; Buckner CD; Petersen FB; Lilleby K; Rowley S; Sanders J; Storb R; Appelbaum FR; Bensinger WI
Bone Marrow Transplant; 1995 Jun; 15(6):907-13. PubMed ID: 7581090
[TBL] [Abstract][Full Text] [Related]
16. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide.
Clift RA; Buckner CD; Thomas ED; Bensinger WI; Bowden R; Bryant E; Deeg HJ; Doney KC; Fisher LD; Hansen JA
Blood; 1994 Sep; 84(6):2036-43. PubMed ID: 8081005
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of total body irradiation-cyclophosphamide versus busulphan-cyclophosphamide as conditioning regimens for myelogenous leukemia: a meta-analysis].
Xu SX; Tang XH; Chen HQ; Feng B; Xu HQ; Chen XP; Tang XF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1354-60. PubMed ID: 19099643
[TBL] [Abstract][Full Text] [Related]
18. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia.
Davies SM; Ramsay NK; Klein JP; Weisdorf DJ; Bolwell B; Cahn JY; Camitta BM; Gale RP; Giralt S; Heilmann C; Henslee-Downey PJ; Herzig RH; Hutchinson R; Keating A; Lazarus HM; Milone GA; Neudorf S; Perez WS; Powles RL; Prentice HG; Schiller G; Socié G; Vowels M; Wiley J; Yeager A; Horowitz MM
J Clin Oncol; 2000 Jan; 18(2):340-7. PubMed ID: 10637248
[TBL] [Abstract][Full Text] [Related]
19. Busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation in patients with prior chest radiotherapy.
Van der Jagt RH; Appelbaum FR; Petersen FB; Bigelow CL; Fisher LD; Schoch GH; Buckner CD; Sanders JE; Storb R; Sullivan KM
Bone Marrow Transplant; 1991 Sep; 8(3):211-5. PubMed ID: 1958901
[TBL] [Abstract][Full Text] [Related]
20. [Effect of BU and CY versus TBI and CY as conditioning regimens on the efficacy of haploidentical stem cell transplantation in patients with hematologic malignancy].
Shao Q; Han D; Liu D; Zheng X; Dong L; Wang Z; Ding L; Yan H; Wang H; Duan L
Zhonghua Xue Ye Xue Za Zhi; 2014 Jun; 35(6):505-10. PubMed ID: 24985173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
